Heartburn refractory to proton-pump inhibitors

被引：0
作者：
Trivedi A. [1 ]
Long J.D. [1 ]
机构：
[1] GI Neuromuscular Disorders Program, Section of Gastroenterology, Wake Forest University Baptist Medical Center, Winston-Salem, NC 27157, Medical Center Boulevard
来源：
Current Treatment Options in Gastroenterology | 2007年 / 10卷 / 1期
关键词：
Baclofen; Lansoprazole; Main Drug Interaction; Erosive Esophagitis; Eosinophilic Esophagitis;
D O I：
10.1007/s11938-007-0056-5
中图分类号：
学科分类号：
摘要：
The most appropriate diagnostic and therapeutic approach to patients with heartburn that persists despite the use of proton-pump inhibitor (PPI) therapy currently is not known. In general, patients with heartburn refractory to PPIs may have more than one explanation for their persistent symptoms. These include uncontrolled esophageal acid exposure ("PPI failure") in a small subset of patients, as well as other potential etiologies in the majority of patients who have controlled esophageal acid exposure on PPI therapy ("PPI success"). Some potential explanations for persistent heartburn in this latter group include hypersensitivity to acid reflux, nonacidic or duodenogastric esophageal reflux, as well as functional heartburn. Patients who present with heartburn refractory to PPIs should be investigated further to determine the potential cause. We believe the diagnostic modality with the most clinical usefulness is 24-hour pH and multichannel intraluminal impedance monitoring with symptom index performed while the patient is on high-dose PPI therapy. This approach allows the patient to be properly categorized and also identifies a substantial proportion of patients who will have functional heartburn, a condition that should discourage the use of endoscopic or surgical therapies. Therapeutic options for patients with heartburn refractory to PPIs are limited and have not been thoroughly studied. As a result of the paucity of information, we favor a therapeutic approach based on the outcome of diagnostic testing. Copyright © 2007 by Current Medicine Group LLC.
引用
收藏
页码：47 / 56
页数：9
相关论文
共 37 条
  • [31] Gorelick A.B., Koshy S.S., Hooper F.G., Et al., Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans, Am J Physiol, 275, (1998)
  • [32] Peghini P.L., Katz P.O., Castell D.O., Imipramine decreases oesophageal pain perception in human male volunteers, Gut, 42, pp. 807-813, (1998)
  • [33] Broekaert D., Fischler B., Sifrim D., Et al., Influence of citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: A double-blind, placebo-controlled study, Aliment Pharmacol Ther, 23, pp. 365-370, (2006)
  • [34] Arts J., Tack J., Galmiche J.P., Endoscopic antireflux therapies, Gut, 53, pp. 1207-1214, (2004)
  • [35] Arts J., Lerut T., Rutgeerts P., Et al., A one-year follow-up study of endoluminal gastroplication (Endocinch) in GERD patients refractory to proton pump inhibitor therapy, Dig Dis Sci, 50, pp. 351-356, (2005)
  • [36] Campos G.M., Peters J.H., DeMeester T.R., Et al., Multivariate analysis of factors predicting outcome after laparoscopic Nissen fundoplication, J Gastrointest Surg, 3, pp. 292-300, (1999)
  • [37] Swoger J., Ponsky J., Hicks D.M., Et al., Surgical fundoplication in laryngopharyngeal reflux unresponsive to aggressive acid suppression: A controlled study, Clin Gastroenterol Hepatol, 4, pp. 433-441, (2006)
1234